NASDAQ NMS - GLOBAL MARKET · GILD

+1.28% · +$1.66 · Vol 4.5M

Market closed · last close 4:00 PM ET · price as of 17:26:11 ET

Gilead Sciences, Inc

Biotechnology

$131.70

+ Add to watchlist

Card

Relationship Map

Veridion Score

Refresh

Score snapshot refresh in progress

Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS

HISTORY WINDOW BUILDING

AI Analysis

Sovereign

Why is GILD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move GILD next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Jul 15
Score
Score moved +13
49/NEUTRAL -> 62/BUY BIAS
Veridion score historySource
Jul 6
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 19
CongressSovereign
Hon. Jared Moskowitz sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 19
CongressSovereign
Jared Moskowitz purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 9
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
May 11
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Feb 26
CongressSovereign
Josh Gottheimer purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Feb 26
CongressSovereign
Hon. Josh Gottheimer sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Feb 6
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt

Catalyst calendar

Dated receipts for GILD are being assembled.

About Gilead Sciences, Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1992

Employees

17K

Country

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$130.09

Day high

$132.95

Day low

$129.41

Previous close

$130.04

52W high

$132.95

-0.94% from high

52W low

$129.41

65% of range

Market cap

$161.5B

P/E

19.83×

EPS

$6.64

Shares out

1.2B

Volume

4.5M

VWAP

$131.71

Price history computed in-house

+1.44%

SMA 50 $130.79 · above

SMA 200 $130.79 · above

52W position 65%

Veridion warehouse edge

Warehouse intelligence for GILD.

Veridion Score

0: 491: 452: 463: 584: 775: 90

Congress 30d

Ro Khanna · Sale

Insider activity

See Form 4 panel below.

13F holders

None on file

Capital Web snapshots checked.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.

Related public evidence

Relationship mapTrace receipt-backed holders and filings around GILD.Congress disclosuresOpen receipt and filing context for GILD.MethodologyReview score inputs, coverage rules, and limitations.

Data ledger

Quote and day range

Refresh interval: 30 seconds

Source: Market data

Veridion Score

Coverage building

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Statements refresh in progress

SEC Form 4 ledger

GILD insider activity

Gilead Sciences, Inc

Score

Coverage building

Pressure

Net selling

Filings

Buys / sells

0 / 19

Net value

-$12.2M

Insiders

Named filers

O'Day Daniel Patrick

Director · Chairman & CEO

Board

Dickinson Andrew D

Chief Financial Officer

C-Suite

Mercier Johanna

Chief Comm & Corp Aff Officer

C-Suite

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$12.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-07-02	2026-07-01	O'Day Daniel Patrick	Director · Chairman & CEO	sell	$126.09	11,900	610,233	$1.5M	SEC Form 4
2026-07-02	2026-07-01	O'Day Daniel Patrick	Director · Chairman & CEO	sell	$127.08	3,100	607,133	$394K	SEC Form 4
2026-06-16	2026-06-15	Dickinson Andrew D	Chief Financial Officer	sell	$125.40	3,000	171,646	$376K	SEC Form 4
2026-06-16	2026-06-15	Mercier Johanna	Chief Comm & Corp Aff Officer	sell	$123.42	1,480	125,754	$183K	SEC Form 4
2026-06-16	2026-06-15	Mercier Johanna	Chief Comm & Corp Aff Officer	sell	$124.00	1,070	124,684	$133K	SEC Form 4

Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 14 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Congress · 90D

Congress filing snapshot refresh in progress

Federal contracts

GILD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for GILD in this window.

Lobbying spend

GILD lobbying filings, year to date.

Registered lobbying filings matched to Gilead Sciences, Inc.

$5.3M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Budget/Appropriations Medicare/MedicaidTrade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue CodeHealth Issues

Filing

$3.2M

GILEAD SCIENCES INC

GILEAD SCIENCES, INC.

Apr 20, 2026

Filing

$1.7M

GILEAD SCIENCES INC

GILEAD SCIENCES, INC.

Jan 20, 2026

Filing

$150.0K